• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

    8/12/21 4:00:00 PM ET
    $DYAI
    $SRNE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $DYAI alert in real time by email
    • Executed binding term sheet with Sorrento Therapeutics (NASDAQ:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic's lead COVID-19 vaccine candidate
    • New collaboration with India's Syngene International to develop a COVID-19 vaccine candidate
    • New co-development collaboration with South Africa's Rubic consortium to establish a basis for researching, developing, and manufacturing multiple other C1 produced vaccines in addition to DYAI-100
    • Potential to support vaccine production for up to 100% of the world's population
    • Dyadic's C1 production platform utilized in ZAPI study published in "VACCINES," a leading peer-reviewed scientific journal
    • Sale of equity interests in BDI Holdings and VLP Bio realizing 1.3 million euros in cash and approximately 30% ROI
    • 66.5% year over year revenue increase
    • Cash and investment grade securities of $25.8 million as of June 30, 2021

    JUPITER, FL / ACCESSWIRE / August 12, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics today announced its financial results for the second quarter of 2021 and highlighted recent Company progress.

    "Since the sale of Dyadic's industrial biotech business to Dupont, we have focused our efforts on using synthetic biology to reengineer our versatile industrially proven C1 protein production platform to address biologic vaccine and drug production for the animal and human health markets. Our research and development continue to advance, having manufactured a C1 produced protein under cGMP manufacturing conditions. Demonstrating that C1 proteins can be manufactured in a cGMP facility, coupled with the successful completion of an interim toxicology study, puts us a step closer in advancing our DYAI-100 COVID-19 vaccine candidate towards a Phase 1 human clinical trial," noted Mark Emalfarb, Dyadic's Founder and Chief Executive Officer.

    "Since March, we have entered into four collaborations, including the recently announced binding term sheet with Sorrento Therapeutics, a drug development partner that has the resources and expertise to advance coronavirus vaccines, therapeutics and diagnostics, both clinically and commercially," continued Mr. Emalfarb. "The Sorrento license agreement, when executed, will mark a significant corporate development milestone as we will have begun to monetize our COVID-19 development efforts through out licensing our C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic's lead COVID-19 vaccine candidate."

    "Through these four agreements, we have started to lay the foundation to enable vaccine development and manufacturing around the globe for the benefit of the most at-risk populations. Our collaborations with Medytox, Syngene and the Rubic Consortium are advancing broad applications of C1 in human health, including combatting COVID-19," concluded Mr. Emalfarb.

    Recent Company Highlights

    • Sorrento Therapeutics License - On August 10, 2021, the Company signed a binding term sheet to enter into a definitive agreement with Sorrento Therapeutics, Inc. ("Sorrento") to outlicense its lead COVID-19 vaccine candidate "DYAI-100" and C1 technology for protein-based coronaviruses vaccines and therapeutics. The definitive agreement is expected to include the following key provisions:
      • Sorrento will obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan), and certain other countries to utilize Dyadic's C1 technology for the development and commercialization of human vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic's lead COVID-19 vaccine candidate.
      • Exclusivity is subject to Sorrento's timely achievement of certain development milestones.
      • Sorrento will obtain non-exclusive rights in certain animal field of use.
      • Consideration includes a $10 million up-front payment ($5 million in cash and $5 million in Sorrento stock), reimbursement of up to $4 million for DYAI-100 preclinical and clinical development costs incurred by Dyadic, and the potential for multiple future development milestones up to $33 million as well as additional royalty payments based on net sales.
      • All future development costs related to this license will be incurred by Sorrento.
    • Other C1 COVID-19 Vaccine Strategic Collaborations
    • Rubic Consortium - A collaboration with South Africa's Rubic Consortium is intended to reduce African dependence on foreign vaccine suppliers. The collaboration agreement includes:
    • Technology transfer and licensing aimed at developing and commercializing vaccine manufacturing and distribution throughout the African continent.
    • A potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through Phase II and Phase III clinical trials.
    • Syngene International - A collaboration with an integrated research, development, and manufacturing services company in India, to develop a COVID-19 vaccine candidate using Dyadic's proprietary C1-cell protein production platform.
    • Medytox - A co-development program with South Korea's Medytox to enable COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g., tetravalent or quadrivalent COVID-19 vaccines). Medytox has begun engineering C1-cells to express COVID-19 variants of concern antigens. Medytox's territory covers the Republic of Korea and multiple Southeast Asian countries.
    • DYAI-100 COVID Vaccine Candidate Update
    • The C1 technology platform has the potential to rapidly develop new highly productive C1-cell lines to produce the SARS-CoV-2 RBD (receptor binding domain) variant antigen. Our goal is to demonstrate that recombinant protein vaccines produced from C1-cells can be manufactured under cGMP conditions in large amounts, at low cost which can gain regulatory approval by showing safety and efficacy for their use in humans. This data is anticipated to further accelerate the adoption and use of our C1 protein production platform to support rapid development and manufacturing of future vaccines, including vaccines for pandemics.
    • We continue to advance DYAI-100 towards initiation of a Phase 1 clinical study.
      • An interim analysis of a toxicology study conducted by Envigo has demonstrated preliminary safety; final toxicology results are expected by October 2021.
      • cGMP production is in process, and once completed, we expect it to put us a step closer in advancing our DYAI-100 COVID-19 vaccine candidate towards a Phase 1 human clinical trial.
      • Later this month, we anticipate meeting with the Paul Ehrlich-Institute (PEI), a German federal agency, medical regulatory body and research institution for vaccines and biomedicines, to discuss the regulatory requirements that will be needed for switching between different COVID-19 variant antigens following the initial Phase 1 study.
    • Sale of equity interests in BDI - On July 27, 2021, the Company sold its equity interests in BDI Holdings and VLP Bio, realizing 1.3 million euros in cash and approximately a 30% ROI. The related gain will be recorded in the third quarter of 2021. BDI remains a valuable resource to perform contract research for us in the future as needed.
    • Zoonotic Anticipation and Preparedness Initiative (ZAPI)

    A peer-reviewed study "Development of a Modular Vaccine Platform for Multimeric Antigen Display Using an Orthobunyavirus Model" demonstrating the successful use of Dyadic's patented and proprietary C1-cell protein production platform to facilitate a fast, coordinated, and practical response to new infectious diseases as soon as they emerge, was published in the peer reviewed journal "VACCINES".

    • Dyadic's C1-cell protein production platform was selected as a fast response vaccine manufacturing model against zoonotic diseases.
    • Our C1-cell platform expressed SBV antigen exhibited efficacy, potency, and safety in veterinary target species.
    • Study demonstrated that recombinant protein-based antigens can be produced from C1-cells at very high yields.
    • C1-cell expressed antigens were successfully used to develop recombinant particle-display vaccines.
    • Management Presentations - The Company presented at the following financial and industry conferences during the period:
      • Jefferies Virtual Healthcare Conference
      • BIO International Convention Digital Conference
      • World Vaccine Congress, Washington
      • 17th Annual PEGS Boston

    FINANCIAL RESULTS

    FOR THE THREE MONTHS ENDED JUNE 30, 2021

    Cash Position: At June 30, 2021, cash, cash equivalents, and the carrying value of investment grade securities, including accrued interest were approximately $25.8 million compared to $29.2 million at December 31, 2020.

    Revenues: Research and development revenue for the three months ended June 30, 2021, increased to approximately $937,000 compared to $524,000 for the same period a year ago.

    Cost of Revenues: Cost of research and development revenue for the three months ended June 30, 2021, increased to approximately $830,000 compared to $624,000 for the same period a year ago.

    The increase in revenue and cost of research and development revenue for the three months ended June 30, 2021, reflected an increased number of on-going research collaborations to eleven compared to nine collaborations for the same period a year ago. There was no provision for contract losses in 2021.

    R&D Expenses: Research and development expenses for the three months ended June 30, 2021 increased to approximately $2,209,000 compared to $1,116,000 for the same period a year ago. The increase primarily reflected Phase 1 clinical trial cost of DYAI-100, our COVID-19 vaccine in the amount of $1,508,000 offset by a decrease of $415,000 related to our other internal research projects.

    G&A Expenses: General and administrative expenses for the three months ended June 30, 2021, increased by 18.5% to approximately $1,748,000 compared to $1,475,000 for the same period a year ago. The increase principally reflected increases in legal expenses of $117,000, business development and investor relations costs of $65,000, executive and board of director compensation costs of $41,000, insurance expenses of $24,000, and other increases of $26,000.

    Interest Income: Interest income for the three months ended June 30, 2021 was approximately $21,000 compared to $147,000 for the same period a year ago. The decrease was primarily due to the lower balance of hold-to-maturity securities and less reinvestment because of the decrease in interest rate.

    Net Loss: Net loss for the three months ended June 30, 2021 was approximately $3.8 million or $(0.14) per share compared to $2.7 million or $(0.10) per share for the same period a year ago.

    FOR THE SIX MONTHS ENDED JUNE 30, 2021

    Revenues: Research and development revenue for the six months ended June 30, 2021, increased to approximately $1,398,000 compared to $840,000 for the same period a year ago.

    Cost of Revenues: Cost of research and development revenue for the six months ended June 30, 2021, increased to approximately $1,220,000 compared to $902,000 for the same period a year ago.

    The increase in revenue and cost of research and development revenue for the six months ended June 30, 2021 reflected thirteen on-going research collaborations compared to ten collaborations for the same period a year ago. There was no provision for contract losses in 2021.

    R&D Expenses: Research and development expenses for the six months ended June 30, 2021 increased to approximately $4,017,000 compared to $1,872,000 for the same period a year ago. The increase primarily reflected Phase 1 clinical trial cost of DYAI-100, our COVID-19 vaccine in the amount of $2,390,000 offset by a decrease of $245,000 related to our other internal research projects.

    G&A Expenses: General and administrative expenses for the six months ended June 30, 2021, increased by 5.5% to approximately $3,302,000 compared to $3,129,000 for the same period a year ago. The increase principally reflected increases in legal expenses of $159,000, business development and investor relations costs of $60,000, insurance expenses of $39,000, executive and board of director compensation costs of $33,000, offset by reductions in travel and rent expenses of $42,000, and outside services and other decreases of $76,000.

    Interest Income: Interest income for the six months ended June 30, 2021 was approximately $47,000 compared to $315,000 for the same period a year ago. The decrease was primarily due to the lower balance of hold-to-maturity securities and less reinvestment because of the decrease in interest rate.

    Net Loss: Net loss for the six months ended June 30, 2021 was approximately $7.1 million or $(0.26) per share compared to $4.9 million or $(0.18) per share for the same period a year ago.

    Conference Call Information

    Date: Thursday, August 12, 2021
    Time: 5:00 p.m. Eastern Time
    Dial-in numbers: Toll Free: 888-506-0062 International: 973-528-0011
    Webcast Link: https://www.webcaster4.com/Webcast/Page/2031/42318

    An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.dyadic.com for a limited time. To access the replay of the webcast, please follow the webcast link above. A dial-in replay of the call will also be available to those interested. To access the replay, please dial Toll Free: 877-481-4010 (U.S. or Canada) or International: 919-882-2331 (International) and enter replay pass code: 42318.

    About Dyadic International, Inc.

    Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large-scale manufacture of low-cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Certain other research activities are ongoing which include the exploration of using C1 to develop and produce certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. As the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs, and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.

    Please visit Dyadic's website at http://www.dyadic.com for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.

    Safe Harbor Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at http://www.dyadic.com.

    Contact:

    Dyadic International, Inc.
    Ping W. Rawson
    Chief Financial Officer
    Phone: (561) 743-8333
    Email: [email protected]

    DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES
    CONSOLIDATED STATEMENTS OF OPERATIONS

    Three Months Ended June 30, Six Months Ended June 30,
    2021 2020 2021 2020
    Revenues:
    Research and development revenue
    $ 937,092 $ 524,271 $ 1,397,612 $ 839,643
    Costs and expenses:
    Costs of research and development revenue
    829,504 624,240 1,220,266 902,422
    Provision for contract losses
    - 74,955 - 74,955
    Research and development
    2,209,242 1,116,163 4,017,340 1,871,616
    General and administrative
    1,747,614 1,475,232 3,301,621 3,128,624
    Foreign currency exchange loss (gain), net
    17,806 31,690 46,078 42,557
    Total costs and expenses
    4,804,166 3,322,280 8,585,305 6,020,174
    Loss from operations
    (3,867,074) (2,798,009) (7,187,693) (5,180,531)
    Interest income
    20,900 146,587 46,570 314,970
    Net loss
    $ (3,846,174) $ (2,651,422) $ (7,141,123) $ (4,865,561)
    Basic and diluted net loss per common share
    $ (0.14) $ (0.10) $ (0.26) $ (0.18)
    Basic and diluted weighted-average common shares outstanding
    27,645,366 27,467,366 27,589,627 27,459,415

    See Notes to Consolidated Financial Statements in Item 1 of Dyadic's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2021.

    DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES
    CONSOLIDATED BALANCE SHEETS

    June 30, 2021 December 31, 2020
    (Unaudited) (Audited)
    Assets
    Current assets:
    Cash and cash equivalents
    $ 14,018,826 $ 20,637,045
    Short-term investment securities
    11,581,911 8,457,452
    Interest receivable
    163,313 112,247
    Accounts receivable
    291,435 294,199
    Prepaid expenses and other current assets
    100,888 280,555
    Total current assets
    26,156,373 29,781,498
    Non-current assets:
    Equity Investment
    284,709 284,709
    Other assets
    6,172 6,225
    Total assets
    $ 26,447,254 $ 30,072,432
    Liabilities and stockholders' equity
    Current liabilities:
    Accounts payable
    $ 2,434,934 $ 1,013,099
    Accrued expenses
    594,803 489,756
    Deferred research and development obligations
    258,748 123,016
    Total current liabilities
    3,288,485 1,625,871
    Commitments and contingencies (Note 4)
    Stockholders' equity:
    Preferred stock, $.0001 par value:
    Authorized shares - 5,000,000; none issued and outstanding
    - -
    Common stock, $.001 par value:
    Authorized shares - 100,000,000; issued shares - 40,332,659 and 39,747,659, outstanding shares - 28,079,157 and 27,494,157 as of June 30, 2021 and December 31, 2020, respectively
    40,333 39,748
    Additional paid-in capital
    99,865,825 98,013,079
    Treasury stock, shares held at cost - 12,253,502
    (18,929,915) (18,929,915)
    Accumulated deficit
    (57,817,474) (50,676,351)
    Total stockholders' equity
    23,158,769 28,446,561
    Total liabilities and stockholders' equity
    $ 26,447,254 $ 30,072,432

    See Notes to Consolidated Financial Statements in Item 1 of Dyadic's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2021.

    SOURCE: Dyadic International, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/659542/Dyadic-Reports-Second-Quarter-2021-Financial-Results-and-Highlights-Recent-Company-Progress

    Get the next $DYAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DYAI
    $SRNE

    CompanyDatePrice TargetRatingAnalyst
    Sorrento Therapeutics Inc.
    $SRNE
    11/2/2022$5.00Overweight
    Cantor Fitzgerald
    Dyadic International Inc.
    $DYAI
    7/18/2022Buy → Neutral
    Dawson James
    Dyadic International Inc.
    $DYAI
    12/17/2021$7.00Buy
    HC Wainwright & Co.
    Sorrento Therapeutics Inc.
    $SRNE
    8/9/2021$30.00 → $26.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DYAI
    $SRNE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

      JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025. Conference Call Information Date: Wednesday, May 14, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560

      5/1/25 3:00:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic to Present at World Vaccine Congress | Washington

      JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines for the efficient large-scale manufacture of proteins for use in human and animal reagents, vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced that Mark Emalfarb, Chief Executive Officer, will present at the 2025 World Vaccine Congress in Washington, D.C. World Vaccine Congress | Washington, D.C.April 22–24, 2025Presentation: Wednesday, April 23, 2025 | 12:40

      4/16/25 2:00:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic Reports 2024 Year-End Financial Results and Business Updates

      Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower costGrowth in commercial pipelines with multiple products nearing market launch, including Human Serum Albumin and DNASe1Expanded alternative protein portfolio with six additional life science products in development for research, nutritional, and cell culture media applicationsContinued advancements in animal and human healthCash and investment-grade securities of $9.3 million as of December 31, 20

      3/26/25 4:05:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    $SRNE
    Financials

    Live finance-specific insights

    See more
    • Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

      JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025. Conference Call Information Date: Wednesday, May 14, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560

      5/1/25 3:00:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic Reports 2024 Year-End Financial Results and Business Updates

      Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower costGrowth in commercial pipelines with multiple products nearing market launch, including Human Serum Albumin and DNASe1Expanded alternative protein portfolio with six additional life science products in development for research, nutritional, and cell culture media applicationsContinued advancements in animal and human healthCash and investment-grade securities of $9.3 million as of December 31, 20

      3/26/25 4:05:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025

      JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the year ended 2024 and host a corporate update conference call on Wednesday, March 26, 2025. Conference Call Information Date: Wednesday, March 26, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-85

      3/12/25 4:00:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    $SRNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kaye Jack exercised 30,000 shares at a strike of $1.33 and covered exercise/tax liability with 27,517 shares, increasing direct ownership by 4% to 59,649 units (SEC Form 4)

      4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

      3/7/25 4:07:16 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Herbst Seth exercised 25,000 shares at a strike of $0.97, increasing direct ownership by 16% to 180,759 units (SEC Form 4)

      4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

      1/8/25 5:19:28 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Kaye Jack converted options into 23,585 shares, increasing direct ownership by 70% to 57,166 units (SEC Form 4)

      4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

      1/7/25 6:08:20 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    $SRNE
    SEC Filings

    See more
    • Dyadic International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)

      5/5/25 5:03:31 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Dyadic International Inc.

      DEFA14A - DYADIC INTERNATIONAL INC (0001213809) (Filer)

      4/29/25 4:33:14 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Dyadic International Inc.

      DEF 14A - DYADIC INTERNATIONAL INC (0001213809) (Filer)

      4/29/25 4:32:22 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    $SRNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

      SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

      2/13/24 4:41:59 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

      SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

      2/1/24 4:15:18 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

      SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

      3/14/23 4:01:06 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    $SRNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Sorrento Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Sorrento Therapeutics with a rating of Overweight and set a new price target of $5.00

      11/2/22 6:29:52 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Dyadic International downgraded by Dawson James

      Dawson James downgraded Dyadic International from Buy to Neutral

      7/18/22 9:59:51 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. initiated coverage on Dyadic International with a new price target

      HC Wainwright & Co. initiated coverage of Dyadic International with a rating of Buy and set a new price target of $7.00

      12/17/21 6:17:22 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    $SRNE
    Leadership Updates

    Live Leadership Updates

    See more
    • Dyadic Appoints Doug Pace to Its Executive Leadership Team

      JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic's management team is in response to the increased interest in the Company's microbial platforms, specifically the C1 technology for infectious disease and

      10/9/23 8:30:00 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors

      PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, to its Board of Directors. Governor Thompson's appointment is effective immediately. Governor Thompson currently serves as the Chief Executive Officer of Thomp

      7/5/22 2:04:42 PM ET
      $SRNE
      $VCKA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji

      SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, as Covid-19 special consultant to Sorrento's Chairman and CEO Henry Ji. Governor Thompson's appointment is effective immediately. Most recently, Thompson served as the President of the University of Wisconsin System from July 2020 through March 2022, one of the largest

      6/24/22 3:38:28 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care